Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to Wu J, Bae J, Chen C, Ryu S, Lozeau D, Stessin A, Prasanna P. Magnetic resonance imaging radiomic analysis of radiation-induced morphea of the breast: a proof-of-concept study. Adv Radiat Oncol 2025;10:101881.

Advances in radiation oncology·2026
Same author

MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia.

Annals of hematology·2026
Same author

[Bioinformatics-Based Screening and Validation of Biomarkers for Sudden Death in Leukemia].

Fa yi xue za zhi·2026
Same author

Therapeutic activation of PPARα contributes to NOTCH1 inhibition in T-cell acute lymphoblastic leukemia.

BMC medicine·2026
Same author

A Multicenter National Study of AL Amyloidosis in China: Insights Into Real-World Diagnosis, Treatment, and Prognosis.

American journal of hematology·2026
Same author

Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma.

PeerJ·2026

Related Experiment Video

Updated: Jun 4, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Integrin alpha8beta1 is Identified as a Potential CAR-T Target for BCMA-Resistant Relapsed Multiple Myeloma.

Suiping Liu1, Jieying Wu1, Jiayu Liu2

  • 1Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, People's Republic of China.

Immunotargets and Therapy
|June 3, 2026
PubMed
Summary

Integrin α8β1 is a novel target for relapsed multiple myeloma after BCMA CAR-T therapy. Targeting ITGA8 may overcome antigen escape and reduce relapse in patients with refractory multiple myeloma.

Keywords:
BCMACAR-T therapyITGA8integrinrelapsed/refractory multiple myeloma

More Related Videos

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: Jun 4, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Chimeric antigen receptor T cell (CAR-T) therapy targeting B cell maturation antigen (BCMA) shows promise for relapsed/refractory multiple myeloma (R/R MM).
  • High rates of relapse persist after BCMA CAR-T due to antigen escape and immune evasion.
  • Novel therapeutic targets are crucial to overcome resistance and improve outcomes in R/R MM.

Purpose of the Study:

  • To identify novel surface antigens associated with relapse after BCMA CAR-T therapy.
  • To evaluate integrin α8β1 (ITGA8) as a potential therapeutic target for R/R MM.
  • To assess the preclinical efficacy of α8β1-targeted CAR-T cells, alone and in combination with BCMA CAR-T.

Main Methods:

  • Analysis of single-cell transcriptomic datasets from patients with R/R MM post-BCMA CAR-T.
  • Characterization of ITGA8 expression in normal and myeloma cells.
  • Generation and preclinical evaluation of α8β1-targeted CAR-T cells in vitro and in vivo.

Main Results:

  • ITGA8 was significantly enriched in multiple myeloma cells at early relapse, identifying a quiescent, immune-evasive subpopulation.
  • ITGA8 expression was absent in normal hematopoietic and immune cells but restricted in vascular smooth muscle cells.
  • α8β1 CAR-T cells effectively lysed ITGA8-positive myeloma cells and demonstrated synergistic tumor control with BCMA CAR-T in antigen-loss models.

Conclusions:

  • Integrin α8β1 represents a promising novel CAR-T target for BCMA-resistant relapsed multiple myeloma.
  • Combination therapy with BCMA and α8β1 CAR-T may improve tumor control and address antigen escape.
  • Further evaluation is needed to confirm clinical efficacy for relapse prevention and assess safety regarding off-tumor expression.